Cost-effectiveness model of recombinant FVIII versus emicizumab treatment of patients with severe hemophilia A without inhibitors
Authors:
Sun S, Wu Y, McDermott M and van Keep M
Publication type:
Conference Proceedings – Poster
Publication Name:
61st American Society of Hematology Annual Meeting
Citation:
Sun S, Wu Y, McDermott M and van Keep M. Cost-effectiveness model of recombinant FVIII versus emicizumab treatment of patients with severe hemophilia A without inhibitors. 61st American Society of Hematology Annual Meeting. Orlando, FL, USA. 7–10 December 2019. Poster 2102.
